Canagliflozin

Canagliflozin is a prescription oral drug belonging to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class, a group of glucose-lowering agents collectively known as gliflozins ^[1]. Marketed principally as Invokana, it was developed by Mitsubishi Tanabe Pharma and is sold by Janssen, a Johnson & Johnson company. It is taken once daily and is used mainly in adults with type 2 diabetes, both to lower blood sugar and, on the strength of later trials, to protect the heart and kidneys ^[1][2].

The drug acts in the kidney rather than on insulin. Under normal conditions the kidneys filter glucose and then reabsorb almost all of it back into the blood, a task performed largely by the SGLT2 transporter in the proximal tubule. Canagliflozin blocks this transporter, so that a portion of filtered glucose is lost in the urine instead of being reclaimed; the resulting glucosuria lowers blood sugar in a way that does not depend on the pancreas releasing insulin ^[1]. Because glucose is excreted along with water and some sodium, the drug also tends to produce modest weight loss, a small drop in blood pressure, and a mild diuretic effect ^[1][3].

Canagliflozin was approved by the US Food and Drug Administration in 2013, making it the first SGLT2 inhibitor cleared for use in the United States. It was initially indicated to improve glycemic control in type 2 diabetes, and its labeling was later broadened as outcome trials demonstrated benefits beyond blood sugar ^[1][2].

Two large randomized programs defined these wider effects. The CANVAS Program, which enrolled people with type 2 diabetes at high cardiovascular risk, found that canagliflozin reduced major cardiovascular events, but it also recorded an unexpected increase in lower-limb amputations, which led regulators to add and, in 2020, later remove a boxed warning as further data accrued ^[1]. The CREDENCE trial, conducted in patients with type 2 diabetes and established kidney disease, was stopped early after canagliflozin clearly slowed the decline toward kidney failure and lowered cardiovascular and renal events ^[2]. Subsequent meta-analyses of SGLT2 inhibitors confirmed a consistent protective effect on kidney outcomes, and modeling studies place canagliflozin among the therapies that can extend cardiovascular and kidney event-free survival in diabetes ^[3][4].

The most common side effects reflect the extra sugar in the urine, chiefly genital yeast infections and urinary tract infections, along with increased urination and, occasionally, dehydration or low blood pressure. Less often the drug can trigger a form of diabetic ketoacidosis that occurs even when blood sugar is only mildly elevated, and rare cases of a serious genital infection called Fournier's gangrene have been reported. As a prescription medicine, it is used under medical supervision and is not available over the counter ^[2][3].

Canagliflozin is prescription only. Because it puts sugar in the urine it raises the risk of genital yeast infections and urinary tract infections, along with more urination and thirst. It can cause volume depletion and dizziness, especially alongside diuretics, and it carries a risk of euglycemic diabetic ketoacidosis, where ketoacidosis develops even with near-normal blood sugar. A rare but serious infection called Fournier's gangrene has been reported, and the CANVAS program flagged higher rates of lower-limb amputation and fracture. It should be held before surgery and during acute illness, and it is less effective for glucose lowering when kidney function is significantly reduced.

Canagliflozin is cleared by glucuronidation rather than by cytochrome P450, so the metabolic interaction that matters is with UGT inducers. Rifampicin cut canagliflozin exposure by 51% in healthy volunteers, and phenytoin, phenobarbital and ritonavir induce UGT1A9 and UGT2B4 the same way; the consequence is loss of glycaemic effect rather than toxicity. Canagliflozin is also a P-glycoprotein substrate and weak inhibitor, and it raised digoxin exposure by 20% and peak concentration by 36%, which is enough to matter for a drug with that narrow a margin.

The pharmacodynamic interactions are more common in practice. Insulin and sulfonylureas combined with canagliflozin cause hypoglycemia that neither reliably causes alone. Loop and thiazide diuretics add to its osmotic diuresis, and the resulting volume depletion produces symptomatic hypotension and acute kidney injury, particularly alongside ACE inhibitors, ARBs or NSAIDs. Potassium-sparing diuretics and RAAS blockade raise hyperkalemia risk.

Checking a whole stack? Run it through interactions + stacks.

The idea of blocking renal glucose reabsorption descends from phlorizin, a glucose-lowering glucoside isolated from apple tree bark in 1835, whose tendency to cause glucosuria inspired more than a century of medicinal chemistry. Canagliflozin itself was discovered by the Japanese firm Mitsubishi Tanabe Pharma and developed jointly with Janssen, a Johnson & Johnson company, which brought it to market. In March 2013 the United States Food and Drug Administration approved it under the brand name Invokana, making it the first sodium-glucose cotransporter-2 inhibitor cleared for type 2 diabetes in the United States.

Its cardiovascular and kidney credentials were then established by two large outcome programs; the CANVAS Program reported by Neal and colleagues in 2017 and the kidney-focused CREDENCE trial reported by Perkovic and colleagues in 2019, the latter halted early for efficacy. A separate strand of interest emerged in geroscience when the National Institute on Aging Interventions Testing Program reported in 2020 that canagliflozin extended the lifespan of genetically diverse male mice, moving a diabetes drug squarely into aging research.

Canagliflozin enjoys an unusually strong scientific reputation for a glucose-lowering drug, precisely because its benefits reach well beyond blood sugar. Large, rigorous outcome trials showed that it reduces hospitalization for heart failure and slows the progression of diabetic kidney disease, results that reshaped treatment guidelines and made the gliflozin class a cornerstone of modern cardiometabolic care. What most fascinates researchers, however, is its second life in longevity science; among a handful of interventions ever shown to extend mammalian lifespan, canagliflozin stands out for producing a clear survival benefit in male mice, an effect attributed to blunting daily glucose peaks.

Investigators have since found it can sharpen immune clearance of aged, senescent cells, deepening interest in its geroprotective potential. These findings are genuinely promising, yet honesty requires noting the limits; the mouse lifespan effect was seen only in males, and the CANVAS Program flagged higher rates of lower-limb amputation and fracture, so its profile is best described as powerful but not without caution.